Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryuzo Ohno

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Blood|March 22, 2007
A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 studyNorio Asou, Yuji Kishimoto, Hitoshi Kiyoi, et al.
International Journal of Hematology|January 8, 2010
Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 studyShigeki Ohtake, Shuichi Miyawaki, Hitoshi Kiyoi, et al.
International Journal of Hematology|July 5, 2003
Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0Ritsuro Suzuki, Makoto Murata, Masahiro Kami, et al.
Annals of Hematology|December 3, 2017
Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201Kaito Harada, Noriko Doki, Takeshi Hagino, et al.
International Journal of Hematology|September 11, 2010
Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 studyItsuro Jinnai, Tohru Sakura, Motohiro Tsuzuki, et al.
British Journal of Haematology|November 7, 2008
Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapyMasamitsu Yanada, Isamu Sugiura, Jin Takeuchi, et al.
International Journal of Hematology|April 11, 2009
Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative studyYukio Kobayashi, Kensei Tobinai, Akihiro Takeshita, et al.
Cancer|June 27, 2013
The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studiesMasamitsu Yanada, Shigeki Ohtake, Shuichi Miyawaki, et al.
International Journal of Hematology|June 26, 2010
Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in JapanTadashi Nagai, Jin Takeuchi, Nobuaki Dobashi, et al.
International Journal of Hematology|November 16, 2004
Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical studyYasuo Morishima, Michinori Ogura, Miki Nishimura, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Blood|March 22, 2007
A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 studyNorio Asou, Yuji Kishimoto, Hitoshi Kiyoi, et al.
International Journal of Hematology|January 8, 2010
Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 studyShigeki Ohtake, Shuichi Miyawaki, Hitoshi Kiyoi, et al.
International Journal of Hematology|July 5, 2003
Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0Ritsuro Suzuki, Makoto Murata, Masahiro Kami, et al.
Annals of Hematology|December 3, 2017
Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201Kaito Harada, Noriko Doki, Takeshi Hagino, et al.
International Journal of Hematology|September 11, 2010
Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 studyItsuro Jinnai, Tohru Sakura, Motohiro Tsuzuki, et al.
British Journal of Haematology|November 7, 2008
Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapyMasamitsu Yanada, Isamu Sugiura, Jin Takeuchi, et al.
International Journal of Hematology|April 11, 2009
Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative studyYukio Kobayashi, Kensei Tobinai, Akihiro Takeshita, et al.
Cancer|June 27, 2013
The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studiesMasamitsu Yanada, Shigeki Ohtake, Shuichi Miyawaki, et al.
International Journal of Hematology|June 26, 2010
Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in JapanTadashi Nagai, Jin Takeuchi, Nobuaki Dobashi, et al.
International Journal of Hematology|November 16, 2004
Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical studyYasuo Morishima, Michinori Ogura, Miki Nishimura, et al.
Pageof 8